Tedizolid
- Generic Name
- Tedizolid
- Brand Names
- Sivextro
- Drug Type
- Small Molecule
- Chemical Formula
- C17H15FN6O3
- CAS Number
- 856866-72-3
- Unique Ingredient Identifier
- 97HLQ82NGL
- Background
Drug-resistant bacteria, such as methicillin-resistant Staphylococcus aureus, vancomycin-resistant Enterococcus faecium, and penicillin-resistant Streptococcus penumoniae, represent a massive public health threat. Tedizolid is a member of the oxazolidinone class of antibiotics, which includes the previously approved linezolid and is generally effective again...
- Indication
用于特定的敏感细菌引起的成人急性细菌性皮肤和皮肤结构感染（ABSSSI）。抗菌谱为金黄色葡萄球菌(包括耐甲氧西林和甲氧西林敏感菌株)，化脓性链球菌，无乳链球菌，咽峡炎链球菌群(包括咽峡炎链球菌、中间型链球菌、星群链球菌)，粪肠球菌。
- Associated Conditions
- Acute Bacterial Skin and Skin Structure Infection (ABSSSI)
- Associated Therapies
- -
Outlook 2025: India's CDSCO gives nod to sell 19 new drugs in 2024
In 2024, India's CDSCO approved 19 new drugs, including next-gen therapies for chronic diseases by global majors. Eli Lilly's Mounjaro for diabetes/obesity, Orchid Pharma's Enmetazobactam for resistant bacteria, Cipla's plazomicin for UTIs, Sun Pharma's Etifoxine for anxiety, Dr Reddy's Elobixibat for constipation, and Zydus/Lupin's Vonoprazan for stomach ulcers were notable. New cancer drugs like Eli Lilly's Retevmo and Zydus's nelarabine were also approved.
IMULDOSA™ (ustekinumab-srlf), a Biosimilar to STELARA®, receives FDA approval
Dong-A ST announced FDA approval for Imuldosa™, a biosimilar referencing Stelara®, following the FDA's acceptance of Accord BioPharma's BLA in Oct 2023. Imuldosa targets autoimmune diseases like plaque psoriasis and Crohn’s disease, with global commercialization rights held by Intas Pharmaceuticals. Dong-A ST and Meiji Seika Pharma developed Imuldosa since 2013, with a global license agreement signed in 2021. Accord Healthcare also submitted an MAA to EMA in June 2023.
US FDA Approves Dong-A ST's IMULDOSA™ (ustekinumab-srlf), a Biosimilar to STELARA®
Dong-A ST's Imuldosa™ (ustekinumab-srlf/DMB-3115), a biosimilar referencing Stelara®, receives FDA approval. This marks the company's second FDA-approved biosimilar after Sivextro® in 2014. Imuldosa targets autoimmune diseases like plaque psoriasis and Crohn’s disease, with global commercialization rights held by Intas Pharmaceuticals.
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2024. All Rights Reserved by MedPath